Link between fibrosis-specific biomarkers and interstitial fibrosis in hypertrophic cardiomyopathy

Aleksandra Karabinowska-Małocha1,2, Ewa Dziewięcka3, Magdalena Szymańska4

  • 1Department of Cardiac and Vascular Diseases, Jagiellonian University Medical College, John Paul II Hospital, Kraków, Poland. akarabinowska@gmail.com.

Kardiologia Polska
|July 11, 2023
PubMed

Insights

Galectin-3 levels predict interstitial fibrosis in hypertrophic cardiomyopathy (HCM) patients, as measured by extracellular volume (ECV) via cardiac magnetic resonance. Other fibrosis biomarkers were not useful, but cardiac biomarkers showed a positive correlation with fibrosis.

Area of Science:

  • Cardiology
  • Biomarker Research
  • Medical Imaging

Background:

  • Cardiac fibrosis, particularly interstitial fibrosis, is a significant factor in hypertrophic cardiomyopathy (HCM) with clinical implications.
  • Interstitial fibrosis is less understood compared to replacement fibrosis in HCM.
  • Understanding interstitial fibrosis is crucial for managing HCM progression.

Purpose of the Study:

  • To investigate the association between serum biomarkers and interstitial fibrosis in HCM patients.
  • To assess interstitial fibrosis using extracellular volume (ECV) measured by cardiac magnetic resonance (CMR).
  • To identify potential biomarkers for predicting interstitial fibrosis in HCM.

Main Methods:

  • 50 HCM patients underwent 3T CMR to quantify interstitial fibrosis via ECV.
  • Serum levels of cardiac biomarkers (troponin T, NT-proBNP) and fibrosis biomarkers were measured.
  • Patients were stratified based on median ECV values for comparative analysis.

Main Results:

  • Galectin-3 and body mass index were identified as independent predictors of ECV.
  • Serum galectin-3, troponin T, and NT-proBNP levels significantly correlated with ECV.
  • Patients with higher ECV showed significant differences in NT-proBNP and galectin-3 levels.

Conclusions:

  • Galectin-3 is a valuable independent predictor of interstitial fibrosis in HCM, indicated by elevated ECV.
  • Standard fibrosis-specific biomarkers were not effective in detecting interstitial fibrosis in this HCM cohort.
  • A positive correlation exists between traditional cardiac biomarkers and interstitial fibrosis in HCM patients.
Abstract

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
16
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
202
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
121
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
16
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
10
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K